Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11228022 | 0.97 | NPC1 (0.50) | NPC1LMNAEPHX2ACHESMN1; SMN2 | |
| SCHEMBL15362702 | 0.97 | NPC1 (0.50) | NPC1LMNAEPHX2ACHESMN1; SMN2 | |
| SCHEMBL5236196 | 0.97 | NPC1 (0.50) | NPC1LMNAEPHX2ACHESMN1; SMN2 | |
| SCHEMBL2976961 | 0.97 | NPC1 (0.50) | NPC1LMNAEPHX2ACHESMN1; SMN2 | |
| SCHEMBL18330523 | 0.95 | — | — | |
| SCHEMBL11350663 | 0.93 | NPC1 (0.42) | NPC1EPHX2 | |
| SCHEMBL22414144 | 0.91 | NPC1 (0.45) | NPC1LMNAEPHX2ACHESMN1; SMN2 | |
| SCHEMBL28236249 | 0.91 | NPC1 (0.45) | NPC1LMNAEPHX2ACHESMN1; SMN2 | |
| SCHEMBL12200376 | 0.89 | NPC1 (0.34) | NPC1 | |
| SCHEMBL13652632 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108368016-B | Process for producing cyclopentyl alkyl ether compound | 日本瑞翁株式会社 | 2023-09-26 | — | — | CN | disclosed |
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
| EP-3398928-B1 | METHOD FOR PRODUCING CYCLOPENTYL ALKYL ETHER COMPOUND | ZEON CORP (JP) | 2021-01-20 | — | — | EP | disclosed |
| US-20180354880-A1 | METHOD FOR PRODUCING CYCLOPENTYL ALKYL ETHER COMPOUND | ZEON CORPORATION (JP) | 2018-12-13 | — | — | US | disclosed |
| EP-3398928-A1 | METHOD FOR PRODUCING CYCLOPENTYL ALKYL ETHER COMPOUND | Zeon Corporation (JP) | 2018-11-07 | — | — | EP | disclosed |
| CN-102898149-A | Solvent or solvent composition for manufacturing laminated ceramic member | DAICEL CHEM | 2013-01-30 | — | — | CN | disclosed |
| US-20070265289-A1 | 2-Aminopyrimidine Derivative | ASTELLAS PHARMA INC. (JP) | 2007-11-15 | — | — | US | disclosed |
| US-20070265289-A1 | 2-Aminopyrimidine Derivative | ASTELLAS PHARMA INC. (JP) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | NPC1 859/4885LMNA 2339/4885EPHX2 1579/4885 |
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CD38, CXCR4, FCGRT | NPC1 2619/4885LMNA 1413/4885EPHX2 3254/4885 |
| US-20070265289-A1 | 2-Aminopyrimidine Derivative | NFKBIA, IKBKG, NFKB2 | NPC1 4389/4885LMNA 4358/4885EPHX2 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.